Pancreatic Cancer Market 2019 Global Size, Historical Analysis, Sales Revenue, Development Status, Industry Growth, Future Plans and Opportunity Assessment 2023
Market Research Future published a research report on “Pancreatic Cancer Market Research Report- Global Forecast till 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.
Pune, India – July 1, 2019 /MarketersMedia/ —
Global Pancreatic Cancer Market – Overview
Pancreatic Cancer is an enlarged tumor caused by malignant cells in the tissues of the pancreas. The pancreas are organ situated behind the stomach. Pancreatic cancer can be caused by smoking, drinking alcohol, radiotherapy in the past, genetic factors, age, inflammation of the pancreas, obesity, and diabetes mellitus. According to Cancer Research UK, 7 out of 10 cases of chronic pancreatitis are due to heavy drinking habits.
Rising rates in tobacco consumption, increasing cigarette smokers are likely to enhance the growth of Pancreatic Cancer Market. Additionally, rising prevalence of cancer, increase in intake of alcohol, growing obesity rates, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level.
However high costs, and the side effects related to the treatment of pancreatic cancer are likely to hamper the growth of pancreatic cancer market.
Key Players
There are various market players operating in the global pancreatic cancer market. Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Pfizer, Inc.
Get Free Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1638
Segmentations
The global pancreatic cancer market is segmented on the basis of types, treatment, and end user.
On the basis of the type, it is segmented into endocrine pancreas cancer, exocrine pancreas cancer, and others.
On the basis of the treatment, it is segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy, and others. Furthermore, the chemotherapy is segmented into antimetabolites, anthracyclines, taxanes, and alkylating agents. The targeted therapy is sub-segmented into tyrosine kinase inhibitors and monoclonal antibodies. And the hormone therapy is sub-segmented into estrogen-receptor modulators, aromatase inhibitors, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research institute, and others.
Regional Analysis:
Geographically, the pancreatic cancer market is segmented into four key regions: the Americas, Europe, Asia Pacific, and Middle East & Africa.The Americas is further segmented into North America and South America. And North America is segmented into the U.S. and Canada. Globally, the U.S. is the largest market for pancreatic cancer owing to rising prevalence of cancer, increasing consumption of alcohol, increase in per capita R&D spending, along with rise in demand for new and advanced products and techniques. Similarly increasing healthcare spending is likely to grow the demand for pancreatic cancer market. Similarly, according to CMS (Centres for Medicare and Medicaid Services) U.S. health care spending increased 4.3 percent to reach USD 3.3 trillion per person in 2016.For instance, according to National cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. Similarly, in 2016, U.S. spent over USD 125 billion for cancer care and is expected to spend over USD 156 billion by 2020. According to CDC, around one third of the population is affected with obesity.
Europe accounts for the second largest market due to rising incidence of cancer, growth in research and development to produce advanced technologies, increasing funds, government support and increasing healthcare expenditure. For instance according to Eurostat, Germany spend over EUR 321 billion in the year 2014. Similarly, according to cancer research UK, there were around 9, 921 cases of cancer diagnosed in 2015. This high incidence of cancer is likely to enhance the growth of pancreatic cancer market.
Asia pacific region is expected to be fastest growing region in pancreatic cancer market owing to its growing population and eventually growing patient population. Additionally, increasing healthcare expenditure and growing demand for newer and advanced technologies to treat the growing demand for increasing prevalence of cancer. For instance, US Census Bureau has estimated that by 2050, two third of the world’s older population will reside in Asia.
On the other hand, the Middle East & Africa is expected to witness limited growth due to limited access to the healthcare resources and rising healthcare cost. In the Middle East, the growth of the market is driven by increasing research and development for newer technologies and rising healthcare infrastructure.
Get complete Report @ https://www.marketresearchfuture.com/reports/pancreatic-cancer-market-1638
Intended Audience
• Medical Oncologists
• Oncology Nurses
• Medical Companies
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities
About Us:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Info:
Name: Abhishek Sawant
Email: Send Email
Organization: Market Research Future
Website: https://www.marketresearchfuture.com
Source: MarketersMedia
Release ID: 88891487
Copyright © 1999-2013 SproutNews.com
